- Page 2: HANDBOOK OFSOPs FOR GOODCLINICAL PR
- Page 10: About PolarisClinical Research Cons
- Page 14: Table of ContentsMON-001.0MON-002.0
- Page 18: Initial SubIRB MemberMinutes Templa
- Page 22: SOP# MON-001.0CompanyEffective Date
- Page 26: CompanyStandard Operating Procedure
- Page 30: SOP# MON-002.0CompanyEffective Date
- Page 34: CompanyStandard Operating Procedure
- Page 38: SOP# MON-003.0CompanyEffective Date
- Page 42: SOP# MON-004.0CompanyEffective Date
- Page 46: SOP# MON-004.0CompanyEffective Date
- Page 50: SOP# MON-005.0CompanyEffective Date
- Page 54:
SOP# MON-005.0CompanyEffective Date
- Page 58:
SOP# MON-006.0CompanyEffective Date
- Page 62:
SOP# MON-006.0CompanyEffective Date
- Page 66:
CompanyStandard Operating Procedure
- Page 70:
SOP# MON-007.0CompanyEffective Date
- Page 74:
SOP# MON-007.0CompanyEffective Date
- Page 78:
CompanyStandard Operating Procedure
- Page 82:
SOP# MON-008.0CompanyEffective Date
- Page 86:
SOP# MON-008.0CompanyEffective Date
- Page 90:
SOP# MON-009.0CompanyEffective Date
- Page 94:
SOP# MON-009.0CompanyEffective Date
- Page 98:
SOP# MON-009.0CompanyEffective Date
- Page 102:
SOP# MON-009.0CompanyEffective Date
- Page 106:
SOP# MON-009.0CompanyEffective Date
- Page 110:
SOP# MON-009.0CompanyEffective Date
- Page 114:
SOP# MON-010.0CompanyEffective Date
- Page 118:
SOP# MON-010.0CompanyEffective Date
- Page 122:
CompanyStandard Operating Procedure
- Page 126:
SOP# MON-011.0CompanyEffective Date
- Page 130:
CompanyStandard Operating Procedure
- Page 134:
SOP# MON-012.0CompanyEffective Date
- Page 138:
SOP# MON-012.0CompanyEffective Date
- Page 142:
CompanyStandard Operating Procedure
- Page 146:
CompanyStandard Operating Procedure
- Page 150:
SOP# SITE-001.0CompanyEffective Dat
- Page 154:
SOP# SITE-002.0CompanyEffective Dat
- Page 158:
SOP# SITE-002.0F. Retention of Trai
- Page 162:
SOP# SITE-003.0CompanyEffective Dat
- Page 166:
SOP# SITE-004.0CompanyEffective Dat
- Page 170:
SOP# SITE-005.0CompanyEffective Dat
- Page 174:
SOP# SITE-006.0CompanyEffective Dat
- Page 178:
SOP# SITE-006.0CompanyEffective Dat
- Page 182:
SOP# SITE-007.0CompanyEffective Dat
- Page 186:
CompanyStandard Operating Procedure
- Page 190:
SOP# SITE-008.0CompanyEffective Dat
- Page 194:
CompanyStandard Operating Procedure
- Page 198:
SOP# SITE-009.0CompanyEffective Dat
- Page 202:
SOP# SITE-009.0CompanyEffective Dat
- Page 206:
CompanyStandard Operating Procedure
- Page 210:
SOP# SITE-010.0CompanyEffective Dat
- Page 214:
CompanyStandard Operating Procedure
- Page 218:
SOP# SITE-011.0CompanyEffective Dat
- Page 222:
CompanyStandard Operating Procedure
- Page 226:
CompanyStandard Operating Procedure
- Page 230:
SOP# SITE-013.0CompanyEffective Dat
- Page 234:
SOP# SITE-013.0E. Sponsor ContactsC
- Page 238:
SOP# SITE-014.0CompanyEffective Dat
- Page 242:
SOP# SITE-014.0V. AttachmentsNoneCo
- Page 246:
SOP# IRB-001.0CompanyEffective Date
- Page 250:
CompanyStandard Operating Procedure
- Page 254:
SOP# IRB-002.0CompanyEffective Date
- Page 258:
SOP# IRB-002.0CompanyEffective Date
- Page 262:
CompanyStandard Operating Procedure
- Page 266:
SOP# IRB-003.0CompanyEffective Date
- Page 270:
SOP# IRB-003.0CompanyEffective Date
- Page 274:
SOP# IRB-004.0CompanyEffective Date
- Page 278:
CompanyStandard Operating Procedure
- Page 282:
SOP# IRB-005.0CompanyEffective Date
- Page 286:
SOP# IRB-005.0CompanyEffective Date
- Page 290:
SOP# IRB-006.0CompanyEffective Date
- Page 294:
SOP# IRB-006.0CompanyEffective Date
- Page 298:
CompanyStandard Operating Procedure
- Page 302:
SOP# IRB-007.0CompanyEffective Date
- Page 306:
SOP# IRB-008.0CompanyEffective Date
- Page 310:
CompanyStandard Operating Procedure
- Page 314:
SOP# IRB-009.0CompanyEffective Date
- Page 318:
SOP# IRB-009.0CompanyEffective Date
- Page 322:
CompanyProtocol Amendment FormProto
- Page 326:
CompanyCRF Review FormProtocol #: I
- Page 330:
CompanyDrug Dispensing LogDrug name
- Page 334:
CompanyClinical Trial Materials Dis
- Page 338:
CompanyInvestigational Product Rece
- Page 342:
CompanyScreening and Enrollment Log
- Page 346:
CompanyExpedited Review FormStudy I
- Page 350:
CompanySubject Information and Cons
- Page 354:
CompanySubject Information and Cons
- Page 358:
CompanyStudy Initiation Document Tr
- Page 362:
CompanyInitial Submission Form (con
- Page 366:
CompanyInitial Submission Form (con
- Page 370:
CompanyInitial Submission Form (con
- Page 374:
CompanyIRB Membership RosterMultipl
- Page 378:
CompanyRecommendations (number the
- Page 382:
CompanyThe meeting adjourned at --:
- Page 386:
CompanyMaster Subject LogProtocol #
- Page 390:
CompanyTelephone Contact ReportDate
- Page 394:
CompanyIRB Progress Report Form (co
- Page 398:
CompanyStaff Member’s Name(Please
- Page 402:
CompanyReviewer’s Checklist (cont
- Page 406:
CompanySerious Adverse Subject Init
- Page 410:
CompanySerious Adverse Subject Init
- Page 414:
CompanySerious Adverse Subject Init
- Page 418:
CompanyStudy Site Personnel Signatu
- Page 422:
CompanyIRB Study Termination Acknow
- Page 426:
CompanySummary of SAEsSubjectInitia
- Page 430:
CompanyTraining Record FormEmployee
- Page 434:
CompanyEmployeeExternal programs (L
- Page 438:
CompanyStaff Training Verification
- Page 442:
CompanyPharmacyPharmacist name:Phar
- Page 446:
CompanyStudy Initiation Visit Trip
- Page 450:
CompanyMeeting Content (continued)P
- Page 454:
Company14. Are there any issues con
- Page 458:
CompanyInstitutional Review BoardDo
- Page 462:
CompanyCase Report Form ReviewYes N
- Page 466:
Company40. Has the Investigator sub